Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) indication : for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: Th...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, October 2017
Edition:Version: 1.0
Series:CADTH common drug review
Subjects:
Canada
Ocular Hypertension / Drug Therapy
Glaucoma, Open-angle / Drug Therapy
Cost-benefit Analysis
Travoprost / Economics
Intraocular Pressure
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02011nam a2200337 u 4500
001 EB001865527
003 EBX01000000000000001029607
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190504 r ||| eng
245 0 0 |a CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.)  |h Elektronische Ressource  |b indication : for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension 
246 3 1 |a Drug reimbursement recommendation travoprost 0.003% (Izba) 
246 3 1 |a Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) 
250 |a Version: 1.0 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2017, October 2017 
300 |a 1 PDF file (5 pages) 
653 |a Canada 
653 |a Ocular Hypertension / drug therapy 
653 |a Glaucoma, Open-Angle / drug therapy 
653 |a Cost-Benefit Analysis 
653 |a Travoprost / economics 
653 |a Intraocular Pressure 
710 2 |a CADTH Canadian Drug Expert Committee 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
500 |a "Final." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK535047  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 330 
520 |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: The drug plan cost of treatment with travoprost 0.003% PQ should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA) 

Similar Items